An Innovative Academic Spin-Off with a Multidisciplinary Vision
ADAPTherapeutics is a spin-off of the University of Padua and was founded by a visionary, multidisciplinary team bringing together complementary expertise in basic research, translational science, biotechnology, and regulatory affairs. With decades of combined experience across academia, industry, and public institutions, the founding team enables ADAPTherapeutics to translate cutting-edge scientific innovation into robust and scalable therapeutic development pathways.
Leadership Team
Marco Giorgio, PhD
CEO & Chief Scientific Officer (CSO)
Associate Professor of Biochemistry at the University of Padua. Internationally recognized expert in ageing, epigenetics, and cell plasticity. Author of 150+ publications and former co-founder of a successful biotech spin-off.
Alfredo Errico Provenzano, PhD
Chief Operating Officer (COO)
Biotechnologist with expertise in chromatin biology, gene regulation and multi-omics approaches, integrating experimental and computational methods. Research focused on epigenetic dysregulation in neurodegenerative and age-related diseases. Driven by translational research and therapeutic target discovery.
Giuseppe Persico, PhD
Chief Technology Officer (CTO)
Molecular biologist and bioinformatician specializing in epigenomics and transcriptomics. Expert in bulk, single-cell, and spatial omics data integration. Developer of advanced sequencing and analytical methods for translational research.
Alessandro Monaco, PhD
Chief Financial Officer (CFO)
Global consultant and professor in Regulatory Affairs and Strategic Healthcare Management, with extensive experience at the interface of science, regulation, and policy. Providing critical guidance for translating advanced biomedical research into therapeutic solutions.
Let’s turn scientific insight into real-world impact.
Whether you’re exploring a collaboration, evaluating our platform, or seeking innovative paths in drug discovery, ADAPTherapeutics is ready to engage. We work closely with partners, investors, and research institutions to translate complex biology into actionable therapeutic solutions. Reach out to start a focused, science-driven conversation and discover how our approach can accelerate meaningful progress together.